NCT03269669 2026-03-18
Obinutuzumab With or Without Umbralisib, Lenalidomide, or Combination Chemotherapy in Treating Patients With Relapsed or Refractory Grade I-IIIa Follicular Lymphoma
National Cancer Institute (NCI)
Phase 2 Active not recruiting
Clinical Trials
20 trialsNCT07418190 2026-02-18
Efficacy and Safety of Zanubrutinib, Rituximab, and Lenalidomide (ZR²) in Combination With Tislelizumab for Relapsed/Refractory Follicular Lymphoma
The First Affiliated Hospital with Nanjing Medical University
Phase 2 Recruiting
NCT04792502 2025-12-30
Mosunetuzumab With Lenalidomide Augmentation as First-line Therapy for Follicular and Marginal Zone Lymphoma
Brown University
Phase 2 Recruiting
NCT07299149 2025-12-23
ZGR in TN FL
Institute of Hematology & Blood Diseases Hospital, China
Phase 2 Not yet recruiting
NCT06112847 2025-12-10
Lenalidomide and Epcoritamab for the Treatment of Previously Untreated Follicular Lymphoma
City of Hope Medical Center
Phase 2 Suspended
NCT06792825 2025-08-12
HM2023-43:Ph 2 Trial of Tafasitamab With Lenalidomide+Rituximab in Treatment-naive FL and MZL
Masonic Cancer Center, University of Minnesota
Phase 2 Recruiting
NCT00848328 2025-04-24
Lenalidomide and Rituximab in Treating Patients With Non-Hodgkin Lymphoma
University of California, Davis
Phase 2 Terminated
NCT06549335 2024-10-15
Zanubrutinib, Obinutuzumab and Lenalidomide (ZGR) in High-risk Treatment-naive Patients with Follicular Lymphoma (FL)
Ruijin Hospital
Phase 2 Not yet recruiting
NCT02532257 2024-09-24
Ibrutinib in Combination With Rituximab and Lenalidomide in Treating Patients With Previously Untreated, Stage II-IV Follicular Lymphoma or Marginal Zone Lymphoma
M.D. Anderson Cancer Center
Phase 2 Completed
NCT01393756 2023-12-05
R2-CHOP2
The Lymphoma Academic Research Organisation
Phase 2 Completed
NCT05848765 2023-11-29
REFRACT
University of Birmingham
Phase 2 Recruiting
NCT01216683 2023-06-29
Bendamustine Hydrochloride and Rituximab With or Without Bortezomib Followed by Rituximab With or Without Lenalidomide in Treating Patients With High-Risk Stage II, Stage III, or Stage IV Follicular Lymphoma
Eastern Cooperative Oncology Group
Phase 2 Completed
NCT01307605 2023-06-27
Rituximab With or Without Lenalidomide in Treating Patients With Previously Untreated Follicular Lymphoma
Swiss Cancer Institute
Phase 2 Terminated
NCT00783367 2023-03-30
Combination Therapy Using Lenalidomide (Revlimid)- Low Dose Dexamethasone and Rituximab for Treatment of Rituximab-Resistant, Non-Aggressive B-Cell Lymphomas
Abramson Cancer Center at Penn Medicine
Phase 2 Completed
NCT03019640 2023-02-16
Umbilical Cord Blood NK Cells, Rituximab, High-Dose Chemotherapy, and Stem Cell Transplant in Treating Patients With Recurrent or Refractory B-Cell Non-Hodgkin's Lymphoma
M.D. Anderson Cancer Center
Phase 2 Completed
NCT01419795 2017-07-27
Lenalidomide With or Without Rituximab in Treating Patients With Progressive or Relapsed Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma, Prolymphocytic Leukemia, or Non-Hodgkin Lymphoma Previously Treated With Donor Stem Cell Transplant
Fred Hutchinson Cancer Center
Phase 2 Terminated
NCT00238238 2017-03-15
Rituximab and/or Lenalidomide in Treating Patients With Follicular Non-Hodgkin's Lymphoma That is Not Refractory to Rituximab
Alliance for Clinical Trials in Oncology
Phase 2 Completed
NCT00784927 2016-10-07
Lenalidomide, Rituximab, Cyclophosphamide, and Dexamethasone in Treating Patients With Previously Untreated Low-Grade Non-Hodgkin Lymphoma
Mayo Clinic
Phase 2 Completed
NCT01121757 2016-09-12
Epigenetic Modulation in Relapsed/Refractory Follicular Lymphoma and Marginal Zone Lymphoma
Duke University
Phase 2 Terminated
NCT01307592 2014-01-10
Gemcitabine Hydrochloride, Rituximab, Oxaliplatin, and Lenalidomide in Treating Patients With Relapsed or Refractory, Aggressive Non-Hodgkin Lymphoma
National Cancer Institute (NCI)
Phase 2 Unknown